Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Obinutuzumab Containing Conditioning Regimen for CLL Patients and Patients With Richter's Transformation Requiring an Allogeneic Stem Cell Transplantation

NCT03153514 is registered in ClinicalTrials.gov with German CLL Study Group as lead sponsor.

NCT NCT03153514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03153514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Obinutuzumab Containing Conditioning Regimen for CLL Patients and Patients With Richter's Transformation Requiring an Allogeneic Stem Cell Transplantation
Lead sponsor
German CLL Study Group
Phase
Phase 2
Overall status
Terminated
Start date
November 13, 2017
Completion date
June 6, 2019
Enrollment
3 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, richter's transformation